News

METAvivor is dedicated to the specific fight of women and men living with stage 4 metastatic breast cancer.

Some immune-related adverse events (irAEs) can be life threatening. Researchers in Spain recently published a review of the most common endocrine irAEs and their management strategies.

A recent study explored the link between the genetic mutations and cisplatin-induced hearing loss.

While meeting with your doctor, or after meeting with them, you should keep the definitions of proactive and reactive in mind.

Studies find the addition of rolapitant to the CINV regimen gave a clinically meaningful benefit with no added toxicity.

A study has found that telephone cancer genetic counseling can be just as effective as in-person counseling for women at risk for hereditary breast and ovarian cancer

CURE asked Rebecca Nellis common questions about returning to work during or after cancer treatment.

Stress may have a negative impact on your health but you’re never going to be completely rid of stress. The key isn’t in doing away with all of life’s pressures, but in how you handle them on a daily basis.

New practice guideline now recommends a 2-mm margin width as the standard for patients with DCIS undergoing breast-conserving surgery.

ASCO guidelines on pain management for adult cancer survivors are first of their kind specifically directed to cancer survivors.

Breast cancer is the leading cause of cancer deaths among Black women of all ages and is increasing in younger women in the U.S.

While urinary incontinence and erectile dysfunction are two burdensome side effects from prostate cancer treatment, new online programs are showing promise in helping men cope in both the short and long term.

The National Leiomyosarcoma Foundation believes that a knowledgeable patient is a powerful patient, a patient that is able to be a strong self-advocate.

Despite survivors of childhood cancer doing well, psychosocially, issues could become more apparent later in life.

Melanoma has long been associated with fair skin and a history of sunburns, however, one study shows that overall survival of melanoma in non-white patients is significantly lower than that of white patients.

Having cancer is terrifying. Period. Often, well-intended doctors find themselves unable to mitigate this panic.

An extended-release injection formulation of granisetron (Sustol) has been approved by the FDA for use in combination with other antiemetic therapies for the prevention of CINV, according to the manufacturer of the treatment, Heron Therapeutics.

Patients with cancer who have Medicaid coverage or who are uninsured are more likely to be diagnosed later and receive improper treatment for cancer, according to two recent studies, and these factors can have an impact on their survival.

While primary cytoreductive surgery followed by chemotherapy is the standard of care for newly diagnosed women with advanced ovarian cancer, newly issued practice guidelines suggest that some patients may benefit more from first-line neoadjuvant chemotherapy (NACT) and interval cytoreduction.

A new study has found that overall survival is significantly worse for people of color who are diagnosed with melanoma, even though whites are diagnosed with this deadliest form of skin cancer at a higher rate.

The immunotherapy pembrolizumab (Keytruda) has been granted an accelerated approval from the FDA for the treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease progresses after platinum-based chemotherapy.

When I was diagnosed over six years ago with stage IV anal cancer I loved my job. Very quickly, my work and career took a back seat in my life. But ten months later there I was easing myself back into my job.

Research is pointing to a connection between cisplatin-based chemotherapy and hearing loss in testicular cancer survivors across a wide age range, and the findings may have implications for survivors of other tumors treated with cisplatin as well.

What do patients think about being tested for many genes that may impact their hereditary risk for breast or ovarian cancer, beyond the well-known BRCA mutations?